"L'Hospital de Terrassa és un centre sanitari que forma part del Consorci Sanitari de Terrassa que és una organització sanitària integrada que, disposant de tots els nivells d'atenció, proveeix atenció continuada i coordinada de serveis de salut a una població de 200.000 habitants."

During the past decade, Consorci Sanitari de Terrassa conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 12 clinical trials were completed, i.e. on average, 21.8% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 6 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Consorci Sanitari de Terrassa" #1 sponsor was "Consorci Sanitari de Terrassa" with 15 trials, followed by "Spanish Breast Cancer Research Group" with 12 trials sponsored, "Spanish Lung Cancer Group" with 6 trials sponsored, "Hospital Universitari Vall d'Hebron Research Institute" with 3 trials sponsored and "Cardenal Herrera University" with 3 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Consorci Sanitari de Terrassa" #1 collaborator was "Hoffmann-La Roche" with 6 trials as a collaborator, "Pfizer" with 4 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Austrian Breast & Colorectal Cancer Study Group" with 2 trials as a collaborator and "Breast International Group" with 2 trials as a collaborator. Other collaborators include 102 different institutions and companies that were collaborators in the rest 104 trials.

According to Clinical.Site data, the most researched conditions in "Consorci Sanitari de Terrassa" are "Breast Cancer" (15 trials), "Breast Neoplasms" (4 trials), "HIV Infections" (3 trials), "Non Small Cell Lung Cancer" (3 trials) and "Prostate Cancer" (3 trials). Many other conditions were trialed in "Consorci Sanitari de Terrassa" in a lesser frequency.

Most popular intervention types in "Consorci Sanitari de Terrassa" are "Drug" (48 trials), "Other" (14 trials), "Procedure" (8 trials), "Radiation" (5 trials) and "Behavioral" (4 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (6 trials), "Capecitabine" (4 trials), "Epirubicin" (4 trials), "Paclitaxel" (4 trials) and "Carboplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Consorci Sanitari de Terrassa" are 53 trials for "All" genders, 28 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Consorci Sanitari de Terrassa". 2 are not yet recruiting, 18 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 44 completed trials in Consorci Sanitari de Terrassa, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Consorci Sanitari de Terrassa, 1 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 12 trials, and there were also 14 trials that are defined as “Not Applicable".